Imunon, Inc.
CLSN
Kedudukan dalam Saham
#34970
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Harga Saham
$1.96
Disegerakkan terakhir: 2022-09-20
Modal Pasaran
$4.46M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
122.70%
Negara
US
Perdagangan Imunon, Inc. (CLSN)
Kategori
Healthcare
Modal pasaran bagi Imunon, Inc.(CLSN)
Modal Pasaran: $4.46M
Sehingga October 2026, Imunon, Inc. mempunyai modal pasaran sebanyak $4.46M. Ini menjadikan Imunon, Inc. syarikat ke-34970th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Imunon, Inc. dari 2018 hingga 2026
CLSN berbanding dengan 5 teratas yang paling popular stocks
